High-Throughput Safety Signal Detection for Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes
Dai, H.; Lee, Y. A.; Bian, J.; Guo, J.
Show abstract
ObjectiveTo systematically identify potential safety signals associated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes (T2D) using a high-throughput target trial emulation pipeline applied to real-world data. MethodsWe utilized electronic health record (EHR) data from the OneFlorida+ Data Trust (2012-2023). Using a retrospective new-user cohort design, we compared SGLT2i initiators to initiators of other second-line glucose-lowering drugs (GLDs). We evaluated risk across all ICD-10-CM 4-digit diagnosis codes. A semi-Bayesian shrinkage method was employed to adjust hazard ratios (HR) and p-values to account for multiple testing and stabilize estimates for rare outcomes. ResultsThe analysis identified several statistically significant safety signals. Validating our method, we observed known adverse events such as candidiasis of the vulva and vagina (HR=1.64) and other urogenital fungal infections. We also detected potential signals for conditions such as viral conjunctivitis and melanocytic nevi. ConclusionThis high-throughput screening effectively identified both known and potential new safety signals for SGLT2i. The use of semi-Bayesian shrinkage provides a robust framework for post-marketing surveillance in large healthcare databases.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Finding Long-COVID: Temporal Topic Modeling of Electronic Health Records from the N3C and RECOVER Programs 93%
- Cohort Design and Natural Language Processing to Reduce Bias in Electronic Health Records Research: The Community Care Cohort Project 93%
- Novel clinical subphenotypes in COVID-19: derivation, validation, prediction, temporal patterns, and interaction with social determinants of health 93%
Similar papers in this journal
- Using quantitative bias analysis to adjust for misclassification of COVID-19 outcomes: An applied example of inhaled corticosteroids and COVID-19 outcomes 91%
- Benzodiazepine Initiation Effect on Mortality Among Medicare Beneficiaries Post Acute Ischemic Stroke 91%
- Bias amplification of unobserved confounding in pharmacoepidemiological studies using indication-based sampling: there is no free lunch in restricting the sample to those with a particular drug-indication 89%
Similar papers in this journal
- Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers 90%
- Symptom reporting in over 1 million people: community detection of COVID-19 90%
- Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: an individual-based modelling study 90%
Similar papers in this journal
- Large-scale empirical identification of candidate comparators for pharmacoepidemiological studies 92%
- Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center 91%
- Preventable deaths involving medicines in England and Wales, 2013-22: a systematic case series of coroners’ reports 89%
Similar papers in this journal
- Clinical Impact of Pharmacogenetic Risk Variants in a Large Chinese Cohort 93%
- A Standardized Metric to Enhance Clinical Trial Design and Outcome Interpretation in Type 1 Diabetes 93%
- A unified framework for estimating country-specific cumulative incidence for 18 diseases stratified by polygenic risk 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.